Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2002

01-04-2002 | ORIGINAL ARTICLE

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer

Authors: Y. H. Kim, J. S. Kim, Y. H. Choi, K. H. In, H. S. Park, D. S. Hong, T. J. Jeong, Y. Y. Lee, E. Nam, S. N. Lee, K. S. Lee, H. K. Kim

Published in: International Journal of Clinical Oncology | Issue 2/2002

Login to get access
Metadata
Title
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer
Authors
Y. H. Kim
J. S. Kim
Y. H. Choi
K. H. In
H. S. Park
D. S. Hong
T. J. Jeong
Y. Y. Lee
E. Nam
S. N. Lee
K. S. Lee
H. K. Kim
Publication date
01-04-2002
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 2/2002
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s101470200015

Other articles of this Issue 2/2002

International Journal of Clinical Oncology 2/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine